Additional information
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |
1 / Gastro-oesophageal reflux:
– Treatment of erosive reflux esophagitis,
– Maintenance treatment and prevention of recurrence after healing of esophagitis due to gastroesophageal reflux,
– Symptomatic treatment of gastroesophageal reflux.
2 / In combination with appropriate antibiotic therapy, eradication of Helicobacter pylori for healing of duodenal ulcer in case of infection by Helicobacter pylori and prevention of recurrence of peptic ulcer in case of infection by Helicobacter pylori.
3 / Patients in whom nonsteroidal anti-inflammatory drugs (NSAIDs) must be continued:
– healing of gastric ulcers associated with taking NSAIDs;
– prevention of peptic ulcers associated with taking NSAIDs, in patients at risk.
4 / Treatment of Zollinger-Ellison syndrome. Adolescents from the age of 12
1 / Gastroesophageal reflux disease (GERD):
– Treatment of erosive reflux esophagitis,
– Maintenance treatment and prevention of recurrence after healing of esophagitis due to gastroesophageal reflux,
– Symptomatic treatment of gastroesophageal reflux.
2 / In combination with antibiotics in the treatment of Duodenal ulcer caused by Helicobacter pylori.
Specialty | |
---|---|
Dosage | |
Form | |
Presentation | |
Primary packaging | |
Specification | |
DCI | |
Classement VEIC | |
Therapeutic class | |
Sub Class | |
Laboratory | |
CHART | |
The duration of the conversation | |
Generic / Princeps | |
AMM | |
Date AMM | |
Range |